William E. Pierceall

3.7k total citations
55 papers, 2.5k citations indexed

About

William E. Pierceall is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, William E. Pierceall has authored 55 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 25 papers in Hematology and 24 papers in Oncology. Recurrent topics in William E. Pierceall's work include Multiple Myeloma Research and Treatments (19 papers), Protein Degradation and Inhibitors (19 papers) and Histone Deacetylase Inhibitors Research (6 papers). William E. Pierceall is often cited by papers focused on Multiple Myeloma Research and Treatments (19 papers), Protein Degradation and Inhibitors (19 papers) and Histone Deacetylase Inhibitors Research (6 papers). William E. Pierceall collaborates with scholars based in United States, United Kingdom and Switzerland. William E. Pierceall's co-authors include Honnavara N. Ananthaswamy, Leonard H. Goldberg, Tapas Mukhopadhyay, Jonathan J. Harrington, Douglas W. Mahoney, Anthony P. Shuber, Joel Skoletsky, Stephen N. Thibodeau, David A. Ahlquist and Kevin A. Boynton and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

William E. Pierceall

54 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William E. Pierceall United States	25	1.4k	1.1k	390	371	351	55	2.5k
Michael T. Barrett United States	34	1.9k 1.4×	1.4k 1.2×	608 1.6×	420 1.1×	1.1k 3.1×	99	4.2k
Jean‐Baptiste Telliez United States	28	1.2k 0.9×	807 0.7×	206 0.5×	274 0.7×	232 0.7×	36	2.9k
Vladimir Bezrookove United States	28	2.1k 1.5×	1.0k 0.9×	257 0.7×	135 0.4×	724 2.1×	48	3.3k
Turid Knutsen United States	23	969 0.7×	752 0.7×	359 0.9×	168 0.5×	382 1.1×	37	2.1k
Isidro Sánchez‐García Spain	36	2.7k 2.0×	1.3k 1.2×	381 1.0×	693 1.9×	669 1.9×	115	4.4k
Marion Dorsch United States	32	2.2k 1.6×	1.2k 1.1×	202 0.5×	329 0.9×	591 1.7×	55	3.7k
Clay B. Siegall United States	27	1.2k 0.8×	1.5k 1.3×	472 1.2×	78 0.2×	142 0.4×	60	3.4k
Ryan M. Young United States	19	976 0.7×	809 0.7×	1.2k 3.1×	150 0.4×	312 0.9×	36	2.6k
Rosemary A. Walker United Kingdom	31	1.5k 1.1×	1.0k 0.9×	309 0.8×	52 0.1×	720 2.1×	72	2.8k
John P. McKearn United States	23	1.9k 1.3×	939 0.8×	416 1.1×	514 1.4×	291 0.8×	56	3.7k

Countries citing papers authored by William E. Pierceall

Since Specialization

Citations

This map shows the geographic impact of William E. Pierceall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William E. Pierceall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William E. Pierceall more than expected).

Fields of papers citing papers by William E. Pierceall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William E. Pierceall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William E. Pierceall. The network helps show where William E. Pierceall may publish in the future.

Co-authorship network of co-authors of William E. Pierceall

This figure shows the co-authorship network connecting the top 25 collaborators of William E. Pierceall. A scholar is included among the top collaborators of William E. Pierceall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William E. Pierceall. William E. Pierceall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oekelen, Oliver Van, Michael Amatangelo, Manman Guo, et al.. (2024). Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma. Cell Reports Medicine. 5(6). 101584–101584. 7 indexed citations

Gooding, Sarah, Naser Ansari‐Pour, Kübra Karagoz, et al.. (2022). Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma. Blood. 140(16). 1816–1821. 13 indexed citations

Oekelen, Oliver Van, Michael Amatangelo, Manman Guo, et al.. (2021). Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients. Blood. 138(Supplement 1). 730–730. 7 indexed citations

Gooding, Sarah, Naser Ansari‐Pour, Kübra Karagoz, et al.. (2021). Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients. Blood. 138(Supplement 1). 458–458.

Pierceall, William E., Michael Amatangelo, Nizar J. Bahlis, et al.. (2020). Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 26(22). 5895–5902. 27 indexed citations

Shapiro, Geoffrey I., Patricia LoRusso, Afshin Dowlati, et al.. (2020). A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. British Journal of Cancer. 124(4). 744–753. 83 indexed citations

Amatangelo, Michael, Oliver Van Oekelen, Adeeb Rahman, et al.. (2019). Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients. Blood. 134(Supplement_1). 1775–1775. 9 indexed citations

Ishizawa, Jo, Kensuke Kojima, Teresa McQueen, et al.. (2015). Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs. PLoS ONE. 10(9). e0138377–e0138377. 21 indexed citations

Whitsett, Timothy G., Ian T. Mathews, Michael H. Cardone, et al.. (2014). Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response. Molecular Cancer Research. 12(4). 550–559. 31 indexed citations

10.

Pierceall, William E., Bruno C. Medeiros, Camille Doykan, et al.. (2014). Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia Research. 38(5). 564–568. 11 indexed citations

11.

Pierceall, William E., Steven M. Kornblau, Nicole E. Carlson, et al.. (2013). BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia. Molecular Cancer Therapeutics. 12(12). 2940–2949. 22 indexed citations

12.

Richard, David J., Thomas D. Bannister, William E. Pierceall, et al.. (2013). Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker. Bioorganic & Medicinal Chemistry. 21(21). 6642–6649. 43 indexed citations

13.

Pierceall, William E., Ken A. Olaussen, Vanessa Rousseau, et al.. (2012). Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Annals of Oncology. 23(9). 2245–2252. 54 indexed citations

14.

Pierceall, William E., Kam Sprott, Tuomas Heikkinen, et al.. (2011). Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer. Human Pathology. 43(9). 1363–1375. 2 indexed citations

15.

Ahlquist, David A., Joel Skoletsky, Kevin A. Boynton, et al.. (2000). Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel. Gastroenterology. 119(5). 1219–1227. 399 indexed citations

16.

Pierceall, William E., et al.. (1999). E75 expression in mosquito ovary and fat body suggests reiterative use of ecdysone-regulated hierarchies in development and reproduction. Molecular and Cellular Endocrinology. 150(1-2). 73–89. 72 indexed citations

17.

Pierceall, William E., Amy S. Woodard, Jon S. Morrow, David L. Rimm, & Eric R. Fearon. (1995). Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines.. PubMed. 11(7). 1319–26. 119 indexed citations

18.

Pierceall, William E., Marcella Reale, Albert F. Candia, et al.. (1994). Expression of a Homologue of the Deleted in Colorectal Cancer (DCC) Gene in the Nervous System of Developing Xenopus Embryos. Developmental Biology. 166(2). 654–665. 33 indexed citations

19.

Pierceall, William E., et al.. (1991). Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas. Molecular Carcinogenesis. 4(6). 445–449. 100 indexed citations

20.

Pierceall, William E., Leonard H. Goldberg, & Honnavara N. Ananthaswamy. (1991). Presence of Human Papilloma Virus Type 16 DNA Sequences in Human Nonmelanoma Skin Cancers. Journal of Investigative Dermatology. 97(5). 880–884. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact